Amgen (AMGN) Tops Q4 EPS by 56c, Beats on Revenue; Offers FY26 Guidance

Amgen (NASDAQ: AMGN) reported Q4 EPS of $5.29, $0.56 better than the analyst estimate of $4.73. Revenue for the quarter came in at $9.9 billion versus the consensus estimate of $9.46 billion.

GUIDANCE:

Amgen sees FY2026 EPS of $21.60-$23.00, versus the consensus of $22.10. Amgen sees FY2026 revenue of $37-38.4 billion, versus the consensus of $37.1 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Sandisk targets mid-to-high teens revenue growth through FY2030
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)
• Benchmark Reiterates Buy Rating on Jumia Technologies (JMIA)